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ABSTRACT 
Purpose: Data from epidemiological and experimental studies suggest that 
dietary protein intake may play a role in inhibiting prostate and breast cancer by 
modulating the IGF/AKT/mTOR pathway. In this study we investigated the effects of 
diets with different protein content or quality on prostate and breast cancer.
Experimental Design: To test our hypothesis we assessed the inhibitory effect 
of protein diet restriction on prostate and breast cancer growth, serum PSA and IGF-
1 concentrations, mTOR activity and epigenetic markers, by using human xenograft 
cancer models. 
Results: Our results showed a 70% inhibition of tumor growth in the castrate-
resistant LuCaP23.1 prostate cancer model and a 56% inhibition in the WHIM16 breast 
cancer model fed with a 7% protein diet when compared to an isocaloric 21% protein 
diet. Inhibition of tumor growth correlated, in the LuCaP23.1 model, with decreased 
serum PSA and IGF-1 levels, down-regulation of mTORC1 activity, decreased cell 
proliferation as indicated by Ki67 staining, and reduction in epigenetic markers of 
prostate cancer progression, including the histone methyltransferase EZH2 and the 
associated histone mark H3K27me3. In addition, we observed that modifications of 
dietary protein quality, independently of protein quantity, decreased tumor growth. 
A diet containing 20% plant protein inhibited tumor weight by 37% as compared to 
a 20% animal dairy protein diet. 
Conclusions: Our findings suggest that a reduction in dietary protein intake is 
highly effective in inhibiting tumor growth in human xenograft prostate and breast 




Prostate (PCa) and breast (BC) cancers are the most 
commonly diagnosed cancer in men and women living in 
Western countries [1]. Studies of populations migrating 
from low- to high-risk areas have shown a steep rise in 
PCa and BC rate [2,3]. In addition, in the last three decades 
the age-standardized PCa and BC incidence and mortality 
rate has increased dramatically in Japan and Singapore, 
two developed countries previously considered having 
a very low prevalence rate [4,5]. These studies strongly 
suggest that environmental factors play a key role in PCa 
and BC pathogenesis. It has been hypothesized that this 
increased prevalence of PCa and BC is partially due to 
the radical dietary shifts from traditional to Western diet 
patterns [2,6], which are characterized by high intakes of 
animal protein and fats, and refined carbohydrates. 
Data from epidemiological and experimental studies 
indicate that protein intake is one of the most important 
dietary regulators of circulating levels of IGF-1, a powerful 
growth factor, which activates the Akt/mTOR pathway 
[7,8]. High circulating levels of IGF-1 are associated with 
increased risk of PCa and BC [9-11], Moreover, multiple 
lines of evidence have shown that activation of the PI3K/
AKT/mTOR pathway, through insulin/IGF-1 stimulation 
and/or high levels of essential amino acids, play a crucial 
role in maintaining the malignant phenotype, and its 
inhibition antagonizes growth and motility of a range of 
cancer cells in mouse models [12-17].  
In this study, we assessed whether a reduction of 
protein intake or modifications in aminoacid composition 
of isocaloric diets could inhibit PCa growth by using 
the LuCaP23.1 androgen-sensitive and castrate-resistant 
patient-derived xenograft model. LuCaP23.1 represents 
a relevant model for studying therapeutic interventions 
in a preclinical setting because it retains major clinical 
hallmarks of human PCa, including heterogeneous growth, 
prostate specific antigen (PSA) production, androgen-
responsiveness, and resistance to castration [18]. In 
addition, we assessed whether or not protein intake could 
also inhibit BC growth by using the breast cancer cell line 
WHIM16. Finally, we investigated whether these dietary 
manipulations could modulate IGF-1 production, mTOR 
activity, cell proliferation, and key epigenetic markers of 
PCa progression, such as the methyltransferase EZH2 and 
associated histone mark H3K27me3 [19,20].  
RESULTS
Protein restriction inhibits tumor growth in 
human prostate and breast cancer models. 
To test the hypothesis whether a isocaloric decrease 
in dietary protein intake inhibits tumor growth in a human 
animal model of PCa and BC, we first designed and 
tested murine diets containing the lowest concentrations 
of protein that did not result in weight loss or health 
impairment. These studies showed that an “ad libitum” 
fed diet providing 7% calories from protein provided the 
lowest protein level compatible with health and weight 
maintenance (data not shown). In our first experiment 
(pre-implantation study), we acclimatized 4-6 week old 
male SCID mice to either the 21% or 7% protein diet for 
4 weeks, prior to surgical castration and subcutaneous 
implantation of LuCaP23.1-CR tumors. As shown in 
figure 1A, LuCap23.1-CR xenograft growth was strikingly 
reduced in the 7% than in the 20% protein diet group, 
resulting in a 70% (p< 0.001, 95% CI= 55.98 to 139.7) 
reduced tumor size at 5 weeks post tumor implantation. 
Consistently, average tumor weight at the end of the 
experiment was 81%  (p<0.0009, 95% CI =0.3814-1.243) 
lower in the 7% protein than in the 20% protein diet group 
(Fig. 1B). In a second experiment (post-implantation 
study), protein restriction was initiated in castrated 
mice 4 weeks after tumor establishment (~50 mm2). As 
shown in figure 1E, also in this setting the 7% protein 
diet markedly inhibited tumor growth and resulted in a 
~50% (p<0.0275, 95% CI = 0.04232-0.5910) reduction 
in tumor weight (Fig.1F). Throughout the 4-month study, 
there was no significant difference in mean body weights 
between the 7% and the 21% protein diet groups (Fig. 1C). 
Interestingly, despite the higher carbohydrate content of 
the 7% protein diet, there was no significant difference 
in serum glucose concentration between the two groups 
(Fig. 1D). 
To test the hypothesis whether an isocaloric decrease 
in dietary protein intake inhibits tumor growth in a human 
animal model of BC as well, we acclimatized 4-6 week old 
female NOD-SCID mice to either the 21% or 7% protein 
diet for 4 weeks, prior to subcutaneous implantation of 
WHIM16 tumor cells. As shown in figure 1G, WHIM16 
xenograft growth was significantly reduced in the 7% 
as compared to the 20% protein diet group, resulting in 
a 56% (p< 0.0232, 95% CI= -153.9 to -12.86) reduced 
tumor size. No significant difference in mean body 
weights between the 7% and the 21% protein diet groups 
was observed (Fig. 1H). 
Protein restriction reduces serum IGF-1 
concentration and attenuates mTOR activity in a 
human castrate-resistant, prostate cancer model.
To determine whether dietary protein intake affects 
circulating IGF-1 levels in castrated tumor bearing mice, 
serum IGF-1 concentration were measured in the two 
groups. Serum IGF-1 concentration was significantly lower 
in the 7% than in the 21% protein diet group (Fig. 2A). As 
both serum IGF-1 and amino acids levels are important 
regulators of mTORC1 activity, we were interested in 
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determining whether or not a reduction in protein intake 
down-regulates the mTOR signaling pathway in the 
LuCaP23.1-CR model, and whether or not the diet-induced 
inhibitory effect on tumor growth was dependent on 
mTOR inhibition. To test this hypothesis, we assessed the 
effects on tumor growth and the levels of phosphorylated 
mTOR and p70 S6K in mice treated with diet alone versus 
diet in combination with everolimus treatment. As shown 
in figure 2B and C, everolimus treatment was as effective 
as protein restriction in inhibiting tumor growth and had 
greater effect in combination with protein restriction as 
compared to lower protein diet alone. Tumor weights 
from the animals treated with everolimus alone or the 7% 
protein diet alone were similar (Fig. 2D). However, tumor 
weights were significantly smaller in animals treated with 
everolimus fed the 7% protein diet than in those treated 
with everolimus fed the 20% protein diet, suggesting that 
protein restriction and mTOR inhibition have additive 
inhibitory effects on PCa development. Endpoint PSA 
measurements confirmed the inhibitory effect of protein 
restriction alone and everolimus in both the 21% and 7% 
protein diet groups (Fig. 2E). Immunohistochemistry 
staining showed a significant decrease in phospho-
mTORC1 levels following protein restriction (21% protein 
diet =37% +/- 2.09 vs. 7% protein diet=19% +/- 2.03, 
p<0.0001, 95% CI = 14.51- 26.19), which was even more 
Figure 1: Low protein diet attenuates the growth of prostate and breast cancer in the castrate-resistant LuCaP23.1 
model and in the WHIM16 model, respectively. Tumor sizes were assessed two times a week by caliper measurements. (A, B) 
LuCaP23.1-CR and (G) WHIM16 growth curve of tumors already exposed to low protein diet (pre-implantation studies) and endpoint 
tumor weights. (E, F) LuCap23.1-CR growth curve of tumors exposed to low protein diet after tumors were implanted and established 
(post-implantation studies), and endpoint tumor weights. (C) LuCaP23.1-CR and (H) WHIM16 mouse body weights. (D) Measurements of 
serum glucose in LuCaP23.1-CR bearing mice. Results are expressed as the mean +/- SE, n= 7-10; * p<0.05.
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Figure 2: Low protein diet decreases IGF-1 serum levels and inhibit LuCaP23.1-CR growth in combination with 
everolimus. (A) Measurements of serum IGF-1 in LuCaP23.1-CR bearing animals fed with either 21% or 7% protein diet. (B, C) Mice 
were acclimatized for four weeks to either 21% or 7% protein diet and after LuCaP23.1-CR xenograft implantation were treated with 
everolimus (2 mg/kg PO, daily X5 times/week). (D, E) Endpoint PSA and tumor weights were collected. Results are expressed as the mean 






Figure 3: Low protein diet decreases mTOR and proliferation activity in the LuCaP23.1-CR model. (A) At the end of 
the “pre-implantation” experiment, tumor samples were collected and processed. Paraffin embedded tissue specimens were stained for 
p-mTOR, p-S6 ribosomal protein and proliferation marker Ki67. (B) Quantification of staining. Results are based on four fields per tissue 
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Figure 4: Epigenetic alterations associated with low protein diet in the LuCaP23.1-CR model. (A) At the end of the “pre-
implantation” experiment, tumor samples were collected and processed. Paraffin embedded tissue specimens were stained for the histone 
methyltransferase EZH2 and the associated histone mark H3K27me3. (B) Quantification of staining. Results are based on four randomly 
selected fields and are expressed as the mean + SE. **p<0.01, ***p<0.001
Figure 5: Effect of the different sources of protein diet 
on tumor growth and potential molecular mechanisms. 
Endpoint LuCaP23.1-CR tumor weights of mice fed with either 
21% protein diet (which consist of both plant and animal protein 
sources), 20% or 10% protein diet (plant based) or 20% or 10% 
protein diet (animal based). Results are presented as a mean +/- 
SE, n= 7-8 per group. *p<0.05, ns= not statistically significant. 
Figure 6:  Representative schema of the potential 
molecular mechanisms responsible for the biological 






















































pronounced when protein restriction was combined with 
everolimus (Fig. 3A and B). We also observed a similar 
significant decrease in ribosomal protein TOR activity 
as indicated by the down-regulation of p70 S6K (21% 
protein diet =29%+/- 2.74 vs. 7% protein diet = 8%+/- 
0.84, p<0.0001, 95% CI= 15.4- 27.34) in mice fed the 7% 
protein diet, which is potentiated by everolimus treatment. 
Interestingly, associated with the reduced mTOR activity 
we observed a decreased number of proliferating cells as 
indicated by the Ki67 staining (21% protein diet = 47% 
+/- 4.5 vs. 7% protein diet = 22% +/- 3.4, p<0.0041, 95% 
CI= 11.55- 39.10) (Fig. 3A and B). Protein diet restriction 
induced a similar inhibition of mTOR pathway and Ki67 
expression in another patient-derived xenograft model of 
PCa (supplementary Fig. S1). 
Protein restriction inhibits tumor growth in a 
human androgen-sensitive prostate cancer model.
To determine whether the androgen status could 
affect the inhibitory effects of protein restriction on 
PCa growth, we acclimatized the mice to either 21% 
or 7% protein diet and after four weeks we inoculated 
LuCaP23.1-AS tumors orthotopically in the prostate 
of non-castrated SCID mice. The 7% protein diet had a 
dramatic inhibitory effect on the growth of AS tumors 
implanted orthotopically in the prostate of intact animals 
(supplementary Fig. S2). Interestingly, the effects of 
protein restriction on average tumor weight was identical 
in the animal fed with a 7% diet alone and in those fed a 
21% protein diet treated with everolimus.   
Protein restriction induces epigenetic 
modifications. 
Because in our study the tumor inhibitory effects of 
protein restriction were partially independent of mTOR, 
we assessed whether epigenetic modifications, that are 
known to be associated with PCa progression, were 
modified by protein restriction in the LuCaP23.1-CR 
model. We found that the mice fed with a 7% protein diet 
had significantly lower expression of EZH2 (21% protein 
diet = 97.3% +/- 4.4 vs. 7% protein diet = 55.1% +/- 3.46, 
p<0.0001, 95% CI= 32.8- 51.65) and H3K27me3 (21% 
protein diet =82.3% +/- 4.4 vs. 7% protein diet= 54.9% 
+/- 3.8, p<0.0051, 95% CI= 11.83- 43.02) (Fig. 4A, B and 
C). Similar changes in EZH2 and H3K27me3 were also 
observed in mice treated with everolimus.  
Plant protein diets inhibit tumor growth 
independently of protein content.
To investigate whether modifications in protein 
quality (i.e. aminoacid composition) are beneficial in 
delaying PCa growth, mice were placed on either regular 
(20%) or a reduced (10%) protein diet from animal 
or vegetable sources for 4-weeks prior to surgically 
castration and subcutaneous implantation of LuCaP23.1-
CR xenografts. At the end of the experiment (6 weeks), 
mice were sacrificed and tumor weights were collected. 
As shown in figure 5, a diet containing 20% plant protein 
decreased tumor weight by 37% as compared to a 20% 
animal dairy protein diet (p<0.045, 95% CI= -1.484 to 
-0.01818). The inhibitory effect on tumor growth exerted 
by the 20% and 10% plant protein diets was similar. 
Interestingly, there was no additive effect of switching 
from animal to plant proteins when dietary protein content 
was 10%, suggesting that a threshold exists below which 
the amino acid composition is less important than the 
protein content of the diet. 
DISCUSSION
In this study we examined the effects of isocaloric 
modifications in dietary protein quantity or quality on 
tumor growth in the human xenograft LuCaP23.1 (CR 
and AS), LuCaP35V (CR) and WHIM16 BC models. Our 
findings indicate that dietary protein reduction results in a 
marked inhibition of PCa and BC growth. This inhibitory 
effect was associated with a reduction in serum PSA 
and IGF-1 levels, and a down-regulation of intratumor 
mTOR activity in the LuCaP23.1 LuCaP35V models. 
Protein restriction was also associated with modulation 
of specific histone markers suggesting epigenetic 
modulation. Interestingly, the source of proteins appears 
to be important, as tumor inhibition was also achieved 
by changes in the quality (i.e. aminoacid composition of 
vegetable versus dairy) of protein food. 
Accumulating scientific data indicate that 
perturbations in the IGF/PI3K/Akt/mTOR pathway 
play a key role in the pathogenesis of PCa and BC [10-
18,24]. A linear relationship exists between circulating 
IGF-1 levels and the risk of developing PCa and BC 
[9,10,24], and the PI3K/Akt/mTOR signaling pathways 
is upregulated in 30-50% of PCa [12,13]. Data from 
epidemiological and human experimental studies suggest 
that dietary protein or essential amino acid restriction is 
more powerful than calorie or fat restriction in lowering 
the circulating levels of IGF-1, which in turn inhibits the 
PI3K/AKT/mTOR pathway [7,8,21,23,24]. Consistently, 
our data show that an isocaloric reduction of protein 
intake significantly reduces serum IGF-1 concentrations, 
inhibits mTOR activity, as indicated by a down-regulation 
of phosphorylated mTOR and p70-S6K, and reduces cell 
proliferation as indicated by the decrease in Ki67. In 
addition, our data show that a reduction of diet protein 
intake from 21% to 7% inhibits PCa and BC growth 
by 70% or more both when tumors where implanted 4 
weeks before (pre-implantation studies) or 4 weeks after 
(post-implantation studies) the implementation of protein 
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restriction. This inhibition in PCa growth induced by 
protein restriction appears to be greater than the effect 
induced by fat or carbohydrate restriction previously 
reported by other groups [25-27], and similar to the 
inhibitory effect induced by calorie restriction [28]. We 
also observed an additive effect of protein restriction 
and pharmacological mTOR inhibition (i.e. everolimus 
treatment) on mTOR activity, cell proliferation and PCa 
growth, suggesting that protein restriction works through 
multiple pathways and molecular targets. Interestingly, 
LuCaP23.1 is a PTEN expressing tumor, but with intrinsic 
mTOR pathway activation. Ongoing studies with PCa 
derived from genetically modified mice will determine the 
importance of mTOR activity in the sensitivity to protein 
restriction.   
At least 15-17% (i.e. ~1.3-1.5 g/kg/body weight) 
of the total calories consumed by US and Northern 
European citizens comes from dietary protein, which is 
two-fold higher than what is recommended by the USDA 
(i.e. recommended daily allowance, 0.85 g/kg/body 
weight or 10% protein from calories) and of the quantity 
consumed (9% calorie from protein) by the Okinawan 
centenarians who had one of the lowest rate of PCa and 
BC in the world [29-32]. Moreover, the great majority of 
proteins in the typical Western diet come from meat, egg 
and dairy food sources, which are very rich in essential 
amino acids. Elevated levels of essential amino acids 
are able to fully activate, independently of IGF-1-insulin 
signaling, the TORC1 complex, which regulates cell 
growth, protein synthesis, and autophagy [12]. Our data 
suggest that feeding mice isocaloric and isoproteic diets 
with lower concentrations of some essential aminoacids 
(i.e. isoleucine, lysine, tyrosine, threonine, tryptophan, 
valine and methionine) reduces PCa growth, though at 
a lesser extent than protein restriction. Our experimental 
findings support the notion that the high intake of animal 
(dairy) proteins in Western diets may play a role in PCa 
development and progression, whereas more traditional 
diets rich in proteins from cereals and legumes might 
partially inhibit PCa growth [33].
Epigenetics is a potential mechanistic link between 
diet, energy metabolism, and gene expression modulation 
[34,35]. Highly accessible chromatin or open chromatin 
is typically observed at active regulatory regions like 
enhancers and promoters. Closed chromatin, on the other 
hand, is observed at silenced regions like hyper-methylated 
promoters of repressed genes. Diet and energy metabolism 
affect epigenetic enzymes that regulate histone marks [34-
36]. Enhancer of zeste homolog 2 (EZH2), a subunit of 
Polycomb repressive complex 2, inhibits gene expression 
via its histone methyltransferase activity. A recent 
report has shown that the oncogenic function of EZH2 
in cells of CR prostate cancer is independent of its role 
as a transcriptional repressor and involves its the ability 
to act as a coactivator for critical transcription factors 
including the androgen receptor [16]. Interestingly, in our 
study we observed that protein restriction decreased the 
expression of EZH2 and its associated histone repressive 
marker H3K37me3. This observation suggests that protein 
restriction is responsible for selective epigenetic changes 
that may drive modulation specific pathways involved 
in PCa growth and survival (Fig. 6). Additional studies 
are needed to shed light on the specificity of the histone 
markers and associated gene expression modulation 
following protein restriction.
The results from our studies may have a rapid 
translation into the clinic. We envision that patients with 
recurrent PCa and BC could be offered diet modifications 
involving protein dietary content at different stages of 
their disease with appropriate monitoring. The absence 
of a differential effect in the AS and CR LuCaP23.1 
models suggest that the androgen status does not affect 
the response of PCa to protein restriction.  Furthermore, 
intratumor androgen receptor expression was not inhibited 
in the 7% protein diet group (data not shown).  An ongoing 
clinical study in patients with newly diagnosed PCa will 
provide important information on the biological changes 
following this dietary intervention before prostatectomy. 
In summary, a high-protein diet promoted the growth 
of human LuCaP23.1 and WHIM16 tumors in mice, and 
a reduction in protein intake resulted in a significant 
inhibition of tumor growth even when the diet was 
started after the formation of measurable tumors, possibly 
through inhibition of the IGF/Akt/mTOR pathway and 
epigenetic modifications. Moreover, our findings indicate 
that plant proteins partially inhibit prostate cancer growth 
independently of caloric or proteic intake, suggesting 
that protein quality plays a key role in the progression 
of prostate and breast cancer. Clinical studies in patients 
with prostate and breast cancer are warranted to confirm 
the impact of dietary modifications in protein content and 
quality on tumor progression.   
MATERIALS AND METHODS
Androgen-sensitive and castrate-resistant 
LuCaP23.1 xenograft models of human prostate 
cancer.
Six-weeks old, male homozygous Icr SCID mice 
were purchased from the in-house animal resource 
core facility Roswell Park Cancer Institute (Buffalo, 
NY). Mice were housed and maintained in a sterile and 
pathogen free facility, in accordance with the Institutional 
guidelines credited by the Institutional Animal Care and 
Use Committee.  Castrate-resistant (CR) LuCaP23.1 
xenografts were generated by serial passages of androgen-
sensitive (AS) LuCaP23.1 tumors in surgically-castrated 
mice [18]. LuCaP23.1 AS and CR tumors were dissected 
into ~1 mm2 pieces and implanted either subcutaneously 
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under the skin or orthotopically into the dorsal lobe of 
the prostate in both intact (LuCaP23.1-AS) or surgically-
castrated (LuCaP23.1-CR) mice. Similar approach was 
used for LuCaP35V-CR. All mice were operated under 
sedation with oxygen, isoflurane and buprenorphine. 
Mice were randomly grouped and placed on either 21% 
or 7% protein diets prior to tumor implantation (n=16-20 
per group) or after tumor implantation (n=7 per group) or 
placed on diets from different sources of protein (n= 7-8 
per group).
WHIM16 xenograft model of human breast 
cancer. 
Six-weeks old, female NOD.Cg-Prkdcscid 
Il2rgtm1Wjl/SzJ mice were purchased from the Jackson 
Labs. Mice were housed and maintained in a sterile and 
pathogen free facility.  WHIM16 tumor cell line was 
generated from a patient with ER positive/PR negative/
HER2 negative breast cancer (Washington University). 



















Diet composition Diet composition Diet composition
Total energy value 
(kcal/g) 3.6 3.6
Total energy value 
(kcal/g) 3.7 3.7
Total energy value 
(kcal/g) 3.7 3.7
  Carbohydrate (%Kcal) 58.9 73.0     Carbohydrate (%Kcal) 62.4 73.5     Carbohydrate (%Kcal) 63.6 74.0
  Fat (%kcal) 20.1 20.2     Fat (%kcal) 17.6 16.6     Fat (%kcal) 16.4 16.0
  Protein (%Kcal) 20.9 6.8     Protein (%Kcal) 20.0 10.0     Protein (%Kcal) 20.0 10.0
         Leucine (g/kg) 25.4 8.8             Leucine (g/kg) 21.2 10.6            Leucine (g/kg) 18.7 9.4
         Isoleucine (g/kg) 7.8 2.7             Isoleucine (g/kg) 7.9 4.0            Isoleucine (g/kg) 10.1 5.0
         Lysine (g/kg) 16.3 4.0             Lysine (g/kg) 3.9 1.9            Lysine (g/kg) 15.7 7.9
         Methionine (g/kg) 6.7 1.9             Methionine (g/kg) 4.1 2.1            Methionine (g/kg) 4.9 2.4
         Cysteine (g/kg) 7.2 3             Cysteine (g/kg) 3.0 1.5            Cysteine (g/kg) 2.0 1.0
         Arginine (g/kg) 6.3 2.9             Arginine (g/kg) 7.8 3.9            Arginine (g/kg) 6.7 3.3
      Phenylalanine (g/kg) 6.6 2.4        Phenylalanine (g/kg) 10.4 5.2        Phenylalanine (g/kg) 8.8 4.4
         Tyrosine (g/kg) 6.9 2.4             Tyrosine (g/kg) 5.0 2.5            Tyrosine (g/kg) 9.2 4.6
         Histidine (g/kg) 3.4 1.4             Histidine (g/kg) 4.2 2.1            Histidine (g/kg) 4.9 2.4
         Threonine (g/kg) 9.7 3.3             Threonine (g/kg) 5.5 2.7            Threonine (g/kg) 8.4 4.2
         Tryptophan (g/kg) 3.4 1.0             Tryptophan (g/kg) 1.6 0.8            Tryptophan (g/kg) 2.5 1.2
         Valine (g/kg) 8.4 3.2             Valine (g/kg) 8.7 4.3            Valine (g/kg) 11.8 5.9
Formula (g/kg) Formula (g/kg) Formula (g/kg)
   Corn 430 430    Wheat gluten 110 55    Casein 170 85
   Lactalbumin 177 35    Corn gluten (60%) 136 68    Lactalbumin 44 22
   DL-Methionine 2.0 0.4    Isolated soy protein 22 11    
   Corn starch 149 287.4    Corn starch 325.4 459    Corn starch 380.1 486.3





   Maltodextrin





   Corn oil 29 32    Corn oil 32 32    Corn oil 32 32
   Olive oil 29 32    Olive oil 32 32    Olive oil 32 32
   Cellulose 30 30    Cellulose 50 50    Cellulose 50 50
  * Mineral Mix, AIN-
93G-MX 35 35
  ** Mineral Mix, w/o Ca 
& P 13.4 13.4
   **Mineral Mix, w/o Ca 
& P 13.4 13.4





   Calcium phosphate





   ***Vitamin Mix, 
Tekland 10 10
   ***Vitamin Mix, 
Teklad 10 10
   ***Vitamin Mix, 
Teklad 10 10*Mineral Mix, AIN-93G-MX (No. 94046), **Mineral Mix, w/o Ca & P (No. 98057), *** Vitamin Mix, Teklad (40060),  
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This tumor cell line carries also a PI3K mutation with 
activation of the AKT/mTOR pathway (manuscript 
submitted). Five million WHIM16 cells were implanted 
subcutaneously under the skin. All mice were operated 
under sedation with oxygen, isoflurane and buprenorphine. 
Mice were randomly grouped and placed on either 21% 
or 7% protein diets prior to tumor implantation (n=10 per 
group). 
Feeding protocol and drug treatment. 
The six experimental diets were prepared and 
sterilized by irradiation by Harlan Laboratories (Madison, 
WI). A summary of the composition and ingredients of 
each diet are shown in table 1. Animals were allowed free 
access to food in cage and autoclaved water supply via 
auto-watering system. Male mice that were randomized 
into 21% protein diet and 7% protein diet were further 
randomized within each group to either receive treatment 
with everolimus (10 mg/kg, 5 days on/2 days off) or 
vehicle. 
Tumor assessment.
For tumors implanted subcutaneously, tumor sizes 
and body weights were recorded twice and once a week, 
respectively.  Tumor weights were measured by using a 
weighing scale at the end of the experiments. Tumor sizes 
were assessed by caliper measurements of two diameters 
of the tumor (longest length x shortest length = mm2). 
Blood and prostate tissue collection, and IGF-1 
measurement. 
At the end of the experiment, blood was drawn 
from all mice by cardiac bleed. Serum was separated, 
and aliquots were either used to assess levels of PSA and 
glucose in the serum or stored in -800C for further analysis. 
Serum insulin growth factor 1 (IGF-1) concentration 
was measured in duplicates (n=8 per diet group) using 
a mouse specific IGF-1 ELISA kit (Abcam, Cambridge, 
MA, USA). Tumor tissues were excised, weighed and 
either stored in -800C or fixed in 10% buffered formalin 
for histopathology.
Immunohistochemistry.
Tissue specimens were fixed for 24-hr, paraffin 
embedded and sectioned (4μm). Sections were de-
paraffinized and rehydrated through graded alcohol 
washes. Antigen unmasking was achieved by boiling 
slides in sodium citrate buffer (pH=6.0). Sections 
were further incubated in hydrogen peroxide to reduce 
endogenous activity. To examine the expressions of our 
proteins of interests, tissue section were blocked with 
2.5% horse serum (Vector Laboratories) and incubated 
overnight in primary antibodies against p-mTOR (1:400, 
Cell Signaling), p-S6K (1:200, Cell Signaling), Ki67 
(1:50, Thermo Fisher), EZH2 (1:50, Cell Signaling), and 
H3k27me3 (1:200 Cell Signaling). Following primary 
incubation, tissue sections were incubated in horseradish-
conjugated anti-rabbit or anti-mouse antibody according to 
manufacturer’s protocol (Vector Laboratories) followed by 
enzymatic development in diaminobenzidine (DAB) and 
counter stained in hemotoxyline. Section were dehydrated 
and mounted with cytoseal 60 (Thermo Scientific). 
Stained sections were analyzed under bright field using 
the Zeiss Axio microscope. The number of positive cells 
was determined in a blinded fashion by analyzing four 
random 20x fields per tissue and quantified using Image 
J software. 
Statistical analysis.
Quantitative measures were compared between 
groups (normal diet versus low protein or modified diets, 
with or without treatment) using two-tailed Student’s t-test 
calculated by Graph-Pad software. The P values < 0.05 
were considered to be statistically significant. The data are 
presented as mean ± SE. 
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